Claim Missing Document
Check
Articles

Found 2 Documents
Search

Diagnostic accuracy of GeneXpert in the diagnosis of spinal tuberculosis: A systematic review and meta-analysis Biakto, Karya T.; Kusmawan, I GPY.; Massi, Muhammad N.; Usman, Muhammad A.; Arifin, Jainal
Narra J Vol. 4 No. 2 (2024): August 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i2.925

Abstract

Tuberculosis remains a significant global health issue, with spinal tuberculosis being a severe form of extrapulmonary tuberculosis. Despite the high morbidity associated with spinal tuberculosis, effective and rapid diagnostic methods are limited. The aim of this study was to evaluate the diagnostic accuracy of the GeneXpert compared to other microbiological methods in diagnosing spinal tuberculosis. A systematic review and meta-analysis were conducted following the PRISMA guidelines. Six databases (PubMed, Scopus, EBSCO, EMBASE, ScienceDirect, and Cochrane Central) were searched for relevant studies as of August 31, 2023. Studies were selected based on predefined inclusion criteria, focusing on patients diagnosed with spinal tuberculosis and comparing GeneXpert to microbiological culture, acid-fast bacilli (AFB) staining, and polymerase chain reaction (PCR). Two authors independently performed data extraction and quality assessment, and the meta-analysis was conducted using Meta-DiSc 2.0. Fourteen studies comprising retrospective cohort, prospective cohort, and cross-sectional designs were included. GeneXpert demonstrated a pooled sensitivity of 92% (85–96%) and specificity of 71% (51–86%) compared to culture. AFB smear had the highest specificity at 80% (70–88%) but the lowest sensitivity at 27% (20–35%). The PCR had sensitivity and specificity of 83% (67–92%) and 58% (31–81%), respectively. Substantial heterogeneity was noted across the studies. This study highlighted that GeneXpert had high sensitivity and moderate specificity in diagnosing spinal tuberculosis, making it an alternative to conventional methods. However, further validation through larger, interventional studies is necessary to standardize its use in clinical practice.
Methicillin-Resistant Staphylococcus Aureus in orthopedic surgery: Current evidence from diagnosis until rehabilitative management Handoko, Yosia; Johan, Muhammad P.; Usman, Muhammad A.; Sakti, Muhammad; Arifin, Jainal; Sjahril, Rizalinda; Sultan, Andi Rofian; Pertiwi, Yunialthy Dwia; Yushan, Rafael Marvin; Kusuma, Samuel Andi
Physical Therapy Journal of Indonesia Vol. 7 No. 1 (2026): Inpress January-June 2026
Publisher : Universitas Udayana dan Diaspora Taipei Medical University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/ptji.v7i1.342

Abstract

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a significant threat in orthopaedic surgery. This study aimed to evaluate the current evidence from diagnosis to rehabilitative management of MRSA in orthopedic surgery Methods: This narrative overview synthesized current evidence across the care pathway in orthopaedics, epidemiology and pathogenesis (including key resistance/virulence determinants), diagnostic approaches (sampling strategies and rapid molecular tests), therapeutic strategies (surgery plus tailored antimicrobials and local delivery), rehabilitation considerations, prevention and stewardship programs, and emerging modalities (new antibiotics, bacteriophages, and nanotechnology-enabled delivery). Results: MRSA resistance is primarily mediated by mecA (PBP2a) and augmented by additional virulence factors (e.g., panton-valentine leukocidin). Biofilm on orthopaedic implants protects bacteria from host defences and antibiotics, underpinning recurrent infection. Diagnostic yield improves with deep tissue or implant-associated sampling, while polymerase chain reaction expedites detection of resistance genes to guide early management. Optimal treatment typically combines surgical debridement with implant retention or exchange where appropriate and prolonged, targeted antimicrobials; adjuncts include local antibiotic carriers and negative-pressure wound strategies. Innovative options—novel agents, bacteriophage therapy, and nanotechnology-based delivery—show promise in early studies. Conclusion: Integrated programs, preoperative screening/decolonization, risk-adapted prophylaxis, and antimicrobial stewardship have helped lower MRSA infection rates, yet biofilm biology and rising resistance sustain a substantial burden. Emerging options include linezolid/tedizolid or minocycline plus rifampicin, with efficacy superior to vancomycin, bacteriophage therapy as an adjunct in refractory prosthetic joint infections, and nanotechnology-enabled implant coatings to deter biofilm formation.